{"id":"W2073369621","doi":"10.1007/s10637-005-5862-9","title":"A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada); Jewish General Hospital; Ottawa Regional Cancer Foundation; Cancer Care Ontario","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Adverse effect; Rash; Cancer; Oncology; Nausea; Tolerability; Chemotherapy; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001451174,0.0003242003,0.0006231703,0.0001937972,0.0001356404,0.00001830675,0.00009248948,0.00006718207,0.0005532606],"category_scores_gemma":[0.0001719223,0.0002441685,0.00009567176,0.0003456838,0.0002992915,0.0003908567,0.00005828535,0.0001945071,0.000007276941],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003818092,"about_ca_system_score_gemma":0.0009290089,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001658609,"about_ca_topic_score_gemma":0.00092444,"domain_scores_codex":[0.9978165,0.0001113073,0.0005794399,0.0004246012,0.000738771,0.0003293844],"domain_scores_gemma":[0.9988328,0.0001107536,0.0002411664,0.000147251,0.0003153135,0.0003526894],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2451715,0.04076638,0.5093464,0.0003568845,0.002189781,0.0000616448,0.03198411,0.0004207831,0.01385469,0.001576636,0.01588459,0.1383866],"study_design_scores_gemma":[0.4908887,0.03158554,0.4430284,0.0005820565,0.000652148,0.000006257829,0.0003557333,0.0005365331,0.0261361,0.0004447028,0.004877002,0.0009068357],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945656,0.0002696049,0.000005218146,0.003127043,0.0002207291,0.001216314,0.0003977292,0.00003590792,0.0001618311],"genre_scores_gemma":[0.9950987,0.00002369446,0.002887387,0.0005438323,0.0004471056,0.0001861972,0.0004349463,0.00003566632,0.0003424872],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2457172,"threshold_uncertainty_score":0.9956901,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02695445011454185,"score_gpt":0.3051791641472074,"score_spread":0.2782247140326655,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}